AlaMab is a clinical stage biopharmaceutical company focused on commercializing novel monoclonal antibody therapeutics to benefit patients suffering from indications with significant unmet treatment needs. AlaMab was founded in 2017 and is led by a skilled management and advisory team with substantial experience in antibody and pharmaceutical development.
Qingxi (Charles) Wang PhD — Chairman & CEO
Yanfeng Zhang PhD — President
Scientific Advisory Board
Daniel D. Von Hoff MD,FACP — Co-Chair
Dr. Von Hoff has published more than 741 papers, 143 book chapters, and over 1186 abstracts. Dr. Von Hoff has received many awards throughout his career, including the 2010 American Society of Clinical Oncology (ASCO) David A. Karnofsky Memorial Award, the American Association for Cancer Research (AACR) Distinguished Public Service Award, the 2011 Scripps Genomic Medicine Award, 2014 Hope Funds for Cancer Research Award of Excellence, 2015 Wallace A. Reed MD Award, 2016 OncLive Giant of Cancer Care® designation, 2014 ASCO 50 Oncology Luminaries designation, and among the first class selected in 2013 by the AACR for its Fellows of the AACR Academy.
Dr. Von Hoff was appointed to President Bush’s National Cancer Advisory Board in 2004-2010. Dr. Von Hoff is the past President of the AACR (the world’s largest cancer research organization), a Fellow of the American College of Physicians, and a member and past board member of the American Society of Clinical Oncology. He is a founder of ILEX™ Oncology, Inc. (acquired by Genzyme after Ilex had 2 agents, alemtuzumab and clofarabine, approved by the FDA for patients with leukemia). Dr. Von Hoff is a founder and the Editor Emeritus of Investigational New Drugs – The Journal of New Anticancer Agents and past Editor-in-Chief of Molecular Cancer Therapeutics. He is a co-founder of the AACR/ASCO Methods in Clinical Trial Cancer Research Workshop, which has graduated more than 2100 clinical trial physicians. He is also proud to have been a mentor and teacher for multiple medical students, medical oncology fellows, graduate students, and post-doctoral fellows.
Jean X. Jiang PhD — Co-Chair
Dr. Jiang is an elected Fellow of the American Association for the Advancement of Science (AAAS) and an elected Fellow of the American Society for Bone and Mineral Research. She was honored with the Master Research Award for Distinguished Researcher from the Joe R. and Teresa Lozano Long School of Medicine at UT Health San Antonio in 2017, the UT Health San Antonio Presidential Distinguished Senior Research Scholar Award in 2018 (the highest honor for a researcher at UT Health San Antonio).
Dr. Jiang has published more than 130 papers, including journal articles in Proceedings of the National Academy of Sciences, Developmental Cell, Oncogene, Immunity, and others. She has served as an associate and an editorial board member for multiple journals, including the Journal of Biological Chemistry and Matrix Biology and has served on many U.S. and international research review and advisory panels. Jean is also committed to teaching and mentoring students, postdoctoral fellows and young scientists.